Unknown

Dataset Information

0

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.


ABSTRACT:

Objective

We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 study.

Methods

Patients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16.

Results

Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: -285 dyn s/cm5 (95% CI -357 to -213); p<0.0001) and persistent/recurrent (n=72; -131 dyn s/cm5 (95% CI -214 to -48); p=0.0025) patients. Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6 L/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2 L/min/m2 (95% CI -0.1 to 0.5; p=0.17). Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(-4.7 mm Hg (95% CI -6.9 to -2.6; p<0.0001 and -4.8 mm Hg (-8.2 to -1.5; p=0.0055), respectively). For all patients, changes in 6 min walk distance correlated with changes in PVR (r=-0.29 (95% CI -0.41 to -0.17); p<0.0001) and cardiac index (r=0.23 (95% CI 0.10 to 0.35); p=0.0004).

Conclusions

Riociguat improved haemodynamics in patients with inoperable CTEPH or persistent/recurrent CTEPH.

Trial registration number

NCT00855465.

SUBMITTER: Kim NH 

PROVIDER: S-EPMC5529957 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.

Kim Nick H NH   D'Armini Andrea M AM   Grimminger Friedrich F   Grünig Ekkehard E   Hoeper Marius M MM   Jansa Pavel P   Mayer Eckhard E   Neurohr Claus C   Simonneau Gérald G   Torbicki Adam A   Wang Chen C   Fritsch Arno A   Davie Neil N   Ghofrani Hossein-Ardeschir HA  

Heart (British Cardiac Society) 20161223 8


<h4>Objective</h4>We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 study.<h4>Methods</h4>Patients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or plac  ...[more]

Similar Datasets

| S-EPMC6671827 | biostudies-literature
| S-EPMC9491640 | biostudies-literature
| S-EPMC6540507 | biostudies-literature
| S-EPMC7046957 | biostudies-literature
| S-EPMC8711204 | biostudies-literature
| S-EPMC7959461 | biostudies-literature
| S-EPMC6396196 | biostudies-literature
| S-EPMC5745920 | biostudies-literature
| S-EPMC7489461 | biostudies-literature
| S-EPMC9685142 | biostudies-literature